QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wade, V. L Articles by Gleason, B. L Search for Related Content PubMed PubMed Citation Articles by Wade, V. L Articles by Gleason, B. L

DRUG INFORMATION ROUNDS

Dual Blockade of the Renin–Angiotensin System in Diabetic Nephropathy

Drug Informatics/Ambulatory Care Resident, St. Louis College of Pharmacy, St. Louis, MO

Brenda L Gleason, PharmD

Assistant Professor, Division of Pharmacy Practice, St. Louis College of Pharmacy

Reprints: Vicki L Wade PharmD, St. Louis College of Pharmacy, 4588 Parkview Pl., St. Louis, MO 63110-1088, fax 314/446-8500, vwade{at}stlcop.edu

OBJECTIVE: To review the literature concerning dual blockade of the renin–angiotensin system (RAS) with an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) in diabetic nephrophathy.

DATA SOURCES: MEDLINE (1998–September 2003), EMBASE (1998–September 2003), and International Pharmaceutical Abstracts (1998–September 2003) were used to access the literature. Search terms included angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diabetic nephropathy, dual blockade, renin–angiotensin system, and combination therapy.

DATA SYNTHESIS: Monotherapy with an ACE inhibitor provides incomplete blockade of the RAS. Dual blockade of the RAS has been studied in approximately 300 patients with diabetic nephropathy. Recent randomized controlled studies suggest that dual blockade using an ACE inhibitor and an ARB in diabetic nephropathy is well tolerated and will provide an additional 11–43% reduction in albuminuria versus monotherapy.

CONCLUSIONS: Dual blockade of the RAS using an ACE inhibitor and an ARB provide statistically significant reductions in albuminuria and blood pressure. Use of dual blockade is safe, but requires additional monitoring for hyperkalemia. Long-term studies are needed to determine whether the decrease in albuminuria will correlate with an actual improvement from overt proteinuria to microalbuminuria or a decreased incidence of end-stage renal disease in the overall diabetic population.

Key Words: angiotensin II receptor blocker, angiotensin-converting enzyme inhibitor, diabetic nephropathy, dual blockade, renin–angiotensin system

Published Online, June 8, 2004. www.theannals.com, DOI 10.1345/aph.1D598

This article has been cited by other articles:

				P. P. Dobesh Managing hypertension in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm., June 15, 2006; 63(12): 1140 - 1149. [Abstract] [Full Text] [PDF]

				S. G. Tsouli, E. N. Liberopoulos, D. N. Kiortsis, D. P. Mikhailidis, and M. S. Elisaf Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 1 - 15. [Abstract] [PDF]

				P. De, G. Das, K. Harley, and H. Nair Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 23 - 28. [Abstract] [PDF]